BiOptix announces low cost Surface Plasmon Resonance Services for Colorado-based researchers
BOULDER, Colo., July 8, 2013 /PRNewswire/ -- BiOptix formally announces a unique to the industry research collaboration with the Biophysics Shared Resource Core Facility at the University of Colorado Denver, Anschutz Medical Campus. The collaboration, which is supported by BiOptix, is offering low cost SPR services for Colorado-based researchers on the new BiOptix 404pi, a next-generation surface plasmon resonance platform designed and built in Colorado. The BiOptix 404pi provides label-free analysis of protein-protein kinetics as well as protein-small molecule interactions.
"We are proud to partner with and support the Biophysics Shared Resource Facility at the University of Colorado," noted Ken Wilczek, Vice President of Sales and Marketing for BiOptix. "By offering the use of the new BiOptix 404pi to researchers based in Colorado, BiOptix can both support as well as foster scientific research and activity here in our home state." Researchers from academia as well as industry, who are based in or have principal activities in Colorado, are invited to participate in the program.
The Biophysics Shared Resource Facility is a user facility owned and operated by the Program in Structural Biology and Biochemistry at the University of Colorado, Denver. Since opening in 2001, the group has developed resources to study biomolecular structure and thermodynamics through surface plasmon resonance, CD/ORD, ITC, DSC, fluorescence spectroscopy, and analytical ultracentrifugation (AUC). In addition, the group also offers mass spectroscopy, LC/MS/MS, HPLC and amino acid analysis services. Additional information about the facility as well as the program supported by BiOptix can be found via the following link: http://www.ucdenver.edu/academics/colleges/medicalschool/programs/biomol/strucbiocores/biophysics/Pages/biophysicscorefacilities.aspx
Surface Plasmon Resonance is an advanced and highly sensitive optical technology that measures refractive index changes on a sensor chip's gold surface due to a change in mass that occurs during a binding event. This change can be used to monitor biological interactions such as the concentration of target molecules, kinetic rates and affinity constants. BiOptix has developed and patented a novel ultra-sensitive detection platform known as Enhanced Surface Plasmon resonance, or ESPR. Unlike traditional SPR, ESPR instrumentation from BiOptix enables the high sensitivity of SPR with the high stability and lower noise of common path interferometry.
BiOptix Diagnostics is a privately held firm based in Boulder, Colorado, with leading investments from Boulder Ventures, Remeditex and Rusnano. BiOptix has developed a new class of analytical biosensor instrumentation utilizing a patented high-throughput label-free technology known as ESPR – Enhanced Surface Plasmon Resonance. BiOptix instrumentation allows researchers to study label-free protein-protein and protein-small molecule interaction—with high sensitivity and high throughput. Applications include: Protein-small molecule interactions, protein-protein kinetics, antibody affinities and epitope mapping, oligosaccharide characterization, nucleic acid (DNA-DNA or DNA-RNA) hybridization and biomolecule concentration measurements. Additional information about BiOptix and our products can be found at: www.bioptix.com
More by this Source
BiOptix announces expansion of Innovators Program into Europe
Sep 26, 2013, 09:26 ET
BiOptix announces support of the 8th Annual Next Generation Protein Therapeutics Summit
Jun 26, 2013, 17:39 ET
Browse our custom packages or build your own to meet your unique communications needs.
Learn about PR Newswire services
Request more information about PR Newswire products and services or call us at (888) 776-0942.